NASDAQ:ARGX - arGEN-X BV Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$96.31 -1.48 (-1.51 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$97.79
Today's Range$96.16 - $98.39
52-Week Range$19.00 - $99.99
Volume58,200 shs
Average Volume165,947 shs
Market Capitalization$3.04 billion
P/E Ratio-68.79
Dividend YieldN/A
BetaN/A

About arGEN-X BV (NASDAQ:ARGX)

arGEN-X BV logoargenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARGX
CUSIPN/A
Phone329-310-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio14.14
Quick Ratio14.14

Price-To-Earnings

Trailing P/E Ratio-68.79
Forward P/E Ratio-37.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.74 million
Price / Sales69.25
Cash FlowN/A
Price / CashN/A
Book Value$12.12 per share
Price / Book7.95

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees67
Outstanding Shares32,170,000

arGEN-X BV (NASDAQ:ARGX) Frequently Asked Questions

What is arGEN-X BV's stock symbol?

arGEN-X BV trades on the NASDAQ under the ticker symbol "ARGX."

What price target have analysts set for ARGX?

5 brokerages have issued 1 year price objectives for arGEN-X BV's stock. Their predictions range from $87.00 to $125.00. On average, they anticipate arGEN-X BV's stock price to reach $101.00 in the next year. View Analyst Ratings for arGEN-X BV.

Who are some of arGEN-X BV's key competitors?

Who are arGEN-X BV's key executives?

arGEN-X BV's management team includes the folowing people:
  • Mr. Tim Van Hauwermeiren MSc, EMBA, CEO & Exec. Director (Age 46)
  • Mr. Eric Castaldi, Chief Financial Officer (Age 54)
  • Prof. Hans de Haard Ir, Ph.D., Chief Scientific Officer (Age 58)
  • Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 54)
  • Dr. Torsten Dreier Ph.D., Chief Devel. Officer (Age 54)

When did arGEN-X BV IPO?

(ARGX) raised $65 million in an initial public offering on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has arGEN-X BV been receiving favorable news coverage?

Press coverage about ARGX stock has been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. arGEN-X BV earned a news sentiment score of 0.06 on Accern's scale. They also assigned media stories about the company an impact score of 44.97 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are arGEN-X BV's major shareholders?

arGEN-X BV's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (2.68%), Millennium Management LLC (2.59%), Franklin Resources Inc. (1.41%), Acuta Capital Partners LLC (1.26%), BB Biotech AG (1.23%) and VHCP Management II LLC (1.08%). View Institutional Ownership Trends for arGEN-X BV.

Which institutional investors are selling arGEN-X BV stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Artal Group S.A., DAFNA Capital Management LLC, Franklin Resources Inc., New York State Common Retirement Fund and Bamco Inc. NY. View Insider Buying and Selling for arGEN-X BV.

Which institutional investors are buying arGEN-X BV stock?

ARGX stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, Millennium Management LLC, Loomis Sayles & Co. L P, Citadel Advisors LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Point72 Asset Management L.P. and venBio Select Advisor LLC. View Insider Buying and Selling for arGEN-X BV.

How do I buy shares of arGEN-X BV?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is arGEN-X BV's stock price today?

One share of ARGX stock can currently be purchased for approximately $96.31.

How big of a company is arGEN-X BV?

arGEN-X BV has a market capitalization of $3.04 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. arGEN-X BV employs 67 workers across the globe.

How can I contact arGEN-X BV?

arGEN-X BV's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]


MarketBeat Community Rating for arGEN-X BV (ARGX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about arGEN-X BV and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

arGEN-X BV (NASDAQ:ARGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for arGEN-X BV in the last 12 months. Their average twelve-month price target is $101.00, suggesting that the stock has a possible upside of 4.87%. The high price target for ARGX is $125.00 and the low price target for ARGX is $87.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $101.00$88.25$76.00$37.00
Price Target Upside: 4.87% upside17.92% upside5.57% downside53.46% upside

arGEN-X BV (NASDAQ:ARGX) Consensus Price Target History

Price Target History for arGEN-X BV (NASDAQ:ARGX)

arGEN-X BV (NASDAQ:ARGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018WedbushReiterated RatingOutperform$93.00 ➝ $92.00LowView Rating Details
4/8/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$125.00HighView Rating Details
1/29/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$74.00 ➝ $87.00HighView Rating Details
12/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$100.00LowView Rating Details
8/24/2017CowenReiterated RatingBuyLowView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Dividends

arGEN-X BV (NASDAQ:ARGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

arGEN-X BV (NASDAQ ARGX) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 52.35%
Insider Trading History for arGEN-X BV (NASDAQ:ARGX)
Institutional Ownership by Quarter for arGEN-X BV (NASDAQ:ARGX)

arGEN-X BV (NASDAQ ARGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

arGEN-X BV (NASDAQ ARGX) News Headlines

Source:
DateHeadline
Critical Comparison: arGEN-X BV (ARGX) vs. Its CompetitorsCritical Comparison: arGEN-X BV (ARGX) vs. Its Competitors
www.americanbankingnews.com - May 24 at 1:20 AM
Critical Contrast: arGEN-X BV (ARGX) versus Its RivalsCritical Contrast: arGEN-X BV (ARGX) versus Its Rivals
www.americanbankingnews.com - May 20 at 7:22 PM
arGEN-X BV (ARGX) and Its Rivals Financial SurveyarGEN-X BV (ARGX) and Its Rivals Financial Survey
www.americanbankingnews.com - May 20 at 8:58 AM
arGEN-X BV (ARGX) versus Its Peers Head-To-Head ContrastarGEN-X BV (ARGX) versus Its Peers Head-To-Head Contrast
www.americanbankingnews.com - May 19 at 9:21 PM
arGEN-X BV (ARGX) Expected to Announce Quarterly Sales of $12.17 MillionarGEN-X BV (ARGX) Expected to Announce Quarterly Sales of $12.17 Million
www.americanbankingnews.com - May 19 at 3:58 AM
Contrasting arGEN-X BV (ARGX) & Adaptimmune Therapeutics (ADAP)Contrasting arGEN-X BV (ARGX) & Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - May 18 at 11:24 PM
 Analysts Anticipate arGEN-X BV (ARGX) to Post -$0.43 EPS Analysts Anticipate arGEN-X BV (ARGX) to Post -$0.43 EPS
www.americanbankingnews.com - May 17 at 12:32 PM
Reviewing arGEN-X BV (ARGX) and The CompetitionReviewing arGEN-X BV (ARGX) and The Competition
www.americanbankingnews.com - May 16 at 12:13 PM
arGEN-X BV (ARGX) vs. The Competition Head-To-Head AnalysisarGEN-X BV (ARGX) vs. The Competition Head-To-Head Analysis
www.americanbankingnews.com - May 16 at 1:09 AM
arGEN-X BV (ARGX) & The Competition Head-To-Head ReviewarGEN-X BV (ARGX) & The Competition Head-To-Head Review
www.americanbankingnews.com - May 15 at 11:16 PM
arGEN-X BV (ARGX) Earns Outperform Rating from WedbusharGEN-X BV (ARGX) Earns Outperform Rating from Wedbush
www.americanbankingnews.com - May 10 at 3:06 PM
argenx announces results of Annual General Meeting of Shareholdersargenx announces results of Annual General Meeting of Shareholders
finance.yahoo.com - May 8 at 9:34 AM
arGEN-X BV (ARGX) Receives Consensus Recommendation of "Buy" from BrokeragesarGEN-X BV (ARGX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 4 at 3:22 AM
arGEN-X BV (ARGX) Stock Rating Upgraded by ValuEnginearGEN-X BV (ARGX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
arGEN-X BV (ARGX) Raised to "Hold" at Zacks Investment ResearcharGEN-X BV (ARGX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 6:06 PM
$8.56 Million in Sales Expected for arGEN-X BV (ARGX) This Quarter$8.56 Million in Sales Expected for arGEN-X BV (ARGX) This Quarter
www.americanbankingnews.com - May 1 at 2:04 AM
Q1 2018 EPS Estimates for arGEN-X BV (ARGX) Increased by Piper JaffrayQ1 2018 EPS Estimates for arGEN-X BV (ARGX) Increased by Piper Jaffray
www.americanbankingnews.com - April 30 at 1:04 AM
arGEN-X BV (ARGX) Expected to Announce Earnings of -$0.43 Per SharearGEN-X BV (ARGX) Expected to Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - April 29 at 7:16 PM
Wedbush Increases arGEN-X BV (ARGX) Price Target to $92.00Wedbush Increases arGEN-X BV (ARGX) Price Target to $92.00
www.americanbankingnews.com - April 26 at 12:27 PM
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meetingargenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
finance.yahoo.com - April 24 at 9:37 AM
Zacks: Brokerages Expect arGEN-X BV (ARGX) Will Post Quarterly Sales of $8.56 MillionZacks: Brokerages Expect arGEN-X BV (ARGX) Will Post Quarterly Sales of $8.56 Million
www.americanbankingnews.com - April 14 at 2:02 AM
 Brokerages Expect arGEN-X BV (ARGX) to Post -$0.52 Earnings Per Share Brokerages Expect arGEN-X BV (ARGX) to Post -$0.52 Earnings Per Share
www.americanbankingnews.com - April 12 at 9:16 PM
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112
finance.yahoo.com - April 12 at 10:35 AM
Brokers Offer Predictions for arGEN-X BVs Q1 2018 Earnings (ARGX)Brokers Offer Predictions for arGEN-X BV's Q1 2018 Earnings (ARGX)
www.americanbankingnews.com - April 12 at 7:12 AM
argenx appoints Keith Woods as Chief Operating Officerargenx appoints Keith Woods as Chief Operating Officer
finance.yahoo.com - April 9 at 9:55 AM
arGEN-X BV (ARGX) Given a $125.00 Price Target at SunTrust BanksarGEN-X BV (ARGX) Given a $125.00 Price Target at SunTrust Banks
www.americanbankingnews.com - April 9 at 7:54 AM
arGEN-X BV (ARGX) Receives Average Recommendation of "Buy" from BrokeragesarGEN-X BV (ARGX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 9 at 7:15 AM
 arGEN-X BV (ARGX) Receives Average Recommendation of "Strong Buy" from Brokerages arGEN-X BV (ARGX) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 4 at 11:38 AM
argenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meetingargenx to present complete data from the Phase 2 clinical trial of efgartigimod (ARGX-113) in myasthenia gravis at the American Academy of Neurology Annual Meeting
finance.yahoo.com - April 3 at 9:59 AM
arGEN-X BV (ARGX) Cut to Hold at Zacks Investment ResearcharGEN-X BV (ARGX) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 1:12 PM
argenx announces Annual General Meeting of Shareholders on May 8, 2018argenx announces Annual General Meeting of Shareholders on May 8, 2018
finance.yahoo.com - March 26 at 4:11 PM
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europeargenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe
finance.yahoo.com - March 26 at 10:06 AM
argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseasesargenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases
finance.yahoo.com - March 22 at 9:54 AM
 arGEN-X BV (ARGX) Given Consensus Recommendation of "Strong Buy" by Analysts arGEN-X BV (ARGX) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - March 20 at 10:06 AM
 argenx SE - American Depositary Shares (ARGX) Receives Consensus Recommendation of "Strong Buy" from Analysts argenx SE - American Depositary Shares (ARGX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - March 16 at 11:34 AM
argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodiesargenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies
finance.yahoo.com - March 16 at 10:00 AM
Zacks: argenx SE - American Depositary Shares (ARGX) Given Average Rating of "Strong Buy" by AnalystsZacks: argenx SE - American Depositary Shares (ARGX) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 13 at 1:18 AM
argenx SE’s (EBR:ARGX) Profit Outlookargenx SE’s (EBR:ARGX) Profit Outlook
finance.yahoo.com - March 12 at 10:36 AM
argenx SE - American Depositary Shares (ARGX) Downgraded by Zacks Investment Research to "Sell"argenx SE - American Depositary Shares (ARGX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 7 at 5:26 PM
argenx to Present at Cowen & Company 38th Annual Health Care Conferenceargenx to Present at Cowen & Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:31 AM
argenx reports fourth quarter business update and full year 2017 financial resultsargenx reports fourth quarter business update and full year 2017 financial results
finance.yahoo.com - March 1 at 9:21 AM
Zacks: argenx SE - American Depositary Shares (ARGX) Given $67.67 Average Price Target by AnalystsZacks: argenx SE - American Depositary Shares (ARGX) Given $67.67 Average Price Target by Analysts
www.americanbankingnews.com - February 26 at 3:20 PM
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
finance.yahoo.com - February 22 at 9:27 AM
Zacks: argenx SE - American Depositary Shares (ARGX) Given $67.67 Consensus Target Price by AnalystsZacks: argenx SE - American Depositary Shares (ARGX) Given $67.67 Consensus Target Price by Analysts
www.americanbankingnews.com - February 21 at 9:34 PM
 Analysts Set $67.67 Target Price for argenx SE - American Depositary Shares (ARGX) Analysts Set $67.67 Target Price for argenx SE - American Depositary Shares (ARGX)
www.americanbankingnews.com - February 18 at 11:24 PM
 argenx SE - American Depositary Shares (ARGX) Given $67.67 Average Price Target by Analysts argenx SE - American Depositary Shares (ARGX) Given $67.67 Average Price Target by Analysts
www.americanbankingnews.com - February 15 at 3:30 PM
 argenx SE - American Depositary Shares (ARGX) Receives Consensus Recommendation of "Strong Buy" from Brokerages argenx SE - American Depositary Shares (ARGX) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 30 at 11:46 AM
argenx SE - American Depositary Shares (ARGX) Given New $87.00 Price Target at JMP Securitiesargenx SE - American Depositary Shares (ARGX) Given New $87.00 Price Target at JMP Securities
www.americanbankingnews.com - January 29 at 11:00 AM
 argenx SE - American Depositary Shares (ARGX) Given Consensus Recommendation of "Strong Buy" by Brokerages argenx SE - American Depositary Shares (ARGX) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 22 at 5:18 AM
argenx SE - American Depositary Shares (ARGX) Downgraded by Zacks Investment Researchargenx SE - American Depositary Shares (ARGX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 19 at 6:02 PM

SEC Filings

arGEN-X BV (NASDAQ:ARGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

arGEN-X BV (NASDAQ:ARGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

arGEN-X BV (NASDAQ ARGX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.